Heath has extensive experience investing in healthcare. He opened Novo Ventures’ San Francisco office in 2006, was a founding partner of SightLine Partners, and Managing Director and Head of Biotechnology Venture Investments at Piper Jaffray Ventures. Heath has invested in multiple biotechnology and medical device companies and currently serves as a Director at Synosia, Inogen and NeuroTherapeutics. Prior to his involvement in venture capital, Heath worked as a strategy consultant with McKinsey & Company, serving a range of large and small healthcare clients. Previously, he was founder and CEO of AutoMate Scientific, a San Francisco-based company specialising in biotechnology instrumentation. He has also worked as a bench scientist at Chiron, Cetus and Roche Bioscience in molecular biology, protein chemistry and electrophysiology. Heath earned his PhD in Neuroscience from Stanford University and his undergraduate degree with high honors in Biochemistry from the University of California at Berkeley.